Montreal-basedTheratechnologies Inc.has set a $118,000 annual list price for the just-approved HIV-1 biologic Trogarzo (ibalizumab-uiyk) in the US, though it expects to net 30% less than that after rebates, and plans to launch in six weeks.
The US FDA approved the drug March 6 for multidrug resistant HIV (MDR HIV), that is people with HIV-1 who...






